Sign Up Today and Learn More About Mitra Biotech Stock
Invest in or calculate the value of your shares in Mitra Biotech or other pre-IPO companies through EquityZen's platform.
About Mitra Biotech Stock
Founded
2009
Headquarters
Woburn, MA, US
Total Funding
74.5M
Industries
Software, Artificial Intelligence, Financial Services
Mitra is an innovative biotechnology company dedicated to discover tools to segregate patients for existing and developing anti-cancer treatments. Mitra is addressing significant challenges in personalized cancer medicine with dedicated scientists educated and trained in world famous institutes. Mitra’s discoveries to detect and manage cancer have practical applications and will be moved from the bench to bedside.
Mitra Biotech Press Mentions
Stay in the know about the latest news on Mitra Biotech
Farcast announces ISO 9001 certification human Tumor Microdynamics (hTMD) platform
einpresswire • Aug 16, 2023
Behind the rise of deep tech healthcare startups in Bengaluru
livemint • Jul 28, 2019
This cancer startup drew lessons from a refugee camp
livemint • Jul 28, 2019
Biotech Company Mitra RxDx Raises $40M in Financing
finsmes • Jul 13, 2018
Mitra Biotech Announces CAP Accreditation
prnewswire • Feb 28, 2018
Investors in Mitra Biotech
Discover investors in Mitra Biotech stock and explore their portfolio companies
Mitra Biotech Management
Leadership team at Mitra Biotech
Chief Commercial Officer
Parker Cassidy
Co-Founder & CSO
Pradip Majumder
Join now and verify your accreditation status to gain access to:
- Mitra Biotech Current Valuation
- Mitra Biotech Stock Price
- Mitra Biotech Management
- Available deals in Mitra Biotech and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Mitra Biotech Cap Table and Funding History by Share Class and Liquidity Preferences
- Mitra Biotech Revenue and Financials
- Mitra Biotech Highlights
- Mitra Biotech Business Model
- Mitra Biotech Risk Factors
- Mitra Biotech Research Report from SACRA Research
Trading Mitra Biotech Stock
How to invest in Mitra Biotech stock?
Accredited investors can buy pre-IPO stock in companies like Mitra Biotech through EquityZen funds. These investments are made available by existing Mitra Biotech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Mitra Biotech stock?
Shareholders can sell their Mitra Biotech stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
